Cardiology Clinics 2008-08-01

Role of drug therapy for sustained ventricular tachyarrhythmias.

L Brent Mitchell

Index: Cardiol. Clin. 26(3) , 405-18, vi, (2008)

Full Text: HTML

Abstract

Antiarrhythmic drug therapy, broadly defined, is the mainstay of treatment and prevention of ventricular tachycardia (VT)/ventricular fibrillation (VF), which can lead to sudden death. This article evaluates the evidence for and appropriate use of class I antiarrhythmic drugs, class III antiarrhythmic drugs, beta-blockers, nondihydropyridine calcium-channel blockers, statins, angiotensin enzyme inhibitors, angiotensin receptor blockers, aldosterone blockers, and digoxin for antiarrhythmic benefits in patients who have a propensity for VT/VF and therefore are at risk of sudden death.


Related Compounds

Related Articles:

Azimilide dihydrochloride: a new class III anti-arrhythmic agent.

2000-11-01

[Expert Opin. Investig. Drugs 9(11) , 2705-15, (2000)]

Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro.

2006-07-01

[Europace 8(7) , 549-57, (2006)]

Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias.

2008-02-01

[J. Cardiovasc. Electrophysiol. 19(2) , 172-7, (2008)]

Effects of azimilide on the muscarinic acetylcholine receptor-operated K+ current and experimental atrial fibrillation in guinea-pig hearts.

2007-11-01

[J. Pharmacol. Sci. 105(3) , 229-39, (2007)]

Inhibitory effect of azimilide on Na+/Ca2+ exchange current in guinea-pig cardiac myocytes.

2010-01-01

[J. Pharmacol. Sci. 114(1) , 111-4, (2010)]

More Articles...